VIOLET DAKORA: Open Payments
NPI 1831557982 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,221 in 63 payments from 7 companies in 2025. Trend: 2023 $2,520 · 2024 $1,716 · 2025 $1,221
Food & beverage: $1,146Education: $76
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $326 |
| Teva Pharmaceuticals USA, Inc. | 8 | $252 |
| E.R. Squibb & Sons, L.L.C. | 12 | $197 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $124 |
| Lundbeck LLC | 6 | $118 |
| Janssen Pharmaceuticals, Inc | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $95 |
Products named: INGREZZA, COBENFY, ABILIFY ASIMTUFII, CAPLYTA, UZEDY, AUSTEDO XR, SPRAVATO, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
